Home > Insider Trading > Filing (0000947871-22-000450)

Filing Details

Accession Number:: 0000947871-22-000450
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-04-08 18:06:23
Reporting Period:: 2022-04-06

Accepted Time:: 2022-04-08 18:06:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787306	Arcutis Biotherapeutics Inc.	ARQT	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022-4629	No	No	Yes	No
1157524	Orbimed Capital Llc	601 Lexington Avenue 54Th Floor New York NY 10022	No	No	Yes	No
1760648	Orbimed Capital Gp Vii Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-04-06	162,000	$20.69	4,105,564	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2022-04-06	171,204	$20.69	731,082	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2022-04-07	167,800	$20.66	3,937,764	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2022-04-07	177,196	$20.66	553,886	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2022-04-08	97,200	$20.71	3,840,564	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2022-04-08	102,800	$20.71	451,086	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

These shares of the Issuer's common stock ("Shares") were sold in a block at a price of $20.69.
These shares of the Issuer's common stock ("Shares") were sold in a block at a price of $20.66.
These shares of the Issuer's common stock ("Shares") were sold in a block at a price of $20.71
The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.